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Abstract
Background: Fucose is a deoxyhexose sugar. While the biological roles of L-fucose remain unclear, the sugar is known
to accelerate the malignant potential of cancer cells. Therefore, this study aimed to evaluate the viability pattern of
human cancer and normal cell lines treated with fucose. Methods: The human gingival fibroblast (HGF-1), colorectal
adenocarcinoma (HT-29) and skin malignant melanoma (A375) cell lines were cultured and treated with fucose at three
concentrations of 1, 5, and 10 mg/ml. Cell viability was then measured using (3-(4, 5-dimethylthiazolyl-2)-2, 5diphenyltetrazolium bromide (MTT) assay. The data were analyzed using Statistical Package for the Social Sciences
software. Results: The percentage of HGF-1 cell viability showed a rapid decline after day 1 of treatment. HT-29 and
A375 were capable of surviving treatment with high fucose concentrations. The data were highly significant at p <
0.001. Conclusion: Whereas a high concentration of fucose is toxic to the HGF-1 cell line, the HT-29 and A375 cell
lines could potentially adapt to this condition. Down- or upregulation of certain molecules that could induce or inhibit
cell death may explain such adaptation. Further testing of up- and downregulated molecules should be conducted in
future work.
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cadherin, integrins, and selectin ligands, has also been
reported to influence ligand binding, dimerization, and
signaling capacities.3 Activation of EGFR tyrosine
kinases is a key factor for lung cancer progression. 5
Increased L-fucose in serum has been detected in breast,
oral, head, neck, liver, ovarian, and prostate cancers.3

Introduction
Cancer presents multiple risk factors. Hyperglycemia
has been reported to raise the prevalence and mortality
of certain cancers, such as breast, liver, bladder,
pancreatic, colorectal, and endometrial cancers.1
Hyperglycemia could promote the proliferation,
invasion, and migration of cells and induce apoptotic
resistance.1 This condition is also known to be a factor
for the development of cancer among patients with
diabetes, especially type 2 diabetes.1,2 Fucose is a
natural deoxyhexose sugar with a structure similar to
that of glucose except for its lack of a hydroxyl group
on carbon 6.3 Mammalian cells utilize fucose in the Lenantiomer form, although other deoxyhexoses are used
in the D-enantiomer form. L-Fucose is incorporated
onto glycoproteins during the synthesis of N- and Olinked glycans in mammalian cells.4 Fucosylated
glycans perform several functions, such as
inflammatory response regulation, signal transduction,
cell growth, transcription, and adhesion. For example,
cell–cell interactions can be partially modulated by the
presence of L-fucose-specific lectin-like adhesion
molecules on the cell surface. Fucosylation of cell
membrane receptors and proteins, including epidermal
growth factor receptor (EGFR), TGFβ, Notch, E-

Addition of glycans to glycoproteins is known as
glycosylation. Glycosylation is the major posttranslational
modification of proteins contributing to malignant
transformation and metastasis.6,7 Fucose is a basic
constituent of oligosaccharides and associated with
cancer and inflammation. Increases in fucose level may
lead to altered or unique glycoconjugates.8 Fucose is
one of the essential components of the Lewis ligands,
selectin family that play the important role for cell
adhesion. For instance, during inflammation, E- and Pselectins appear on activated endothelial cells to interact
with leukocytes through sialyl-Lewis (x) and sialylLewis (a) antigens.9 These selectins represent typical
tumor-associated carbohydrate antigens that have been
reported to be responsible for the adhesion of human
cancer cells to the endothelium.10 Fucosylation produces
fucosylated markers, and the upregulation of these
markers could promote canceration. Previous study
reported that key enzymes, such as alpha1,269
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fucosyltransferases (e.g., FUC1 and FUC2), are highly
expressed in malignant tissues, for example, breast
cancer.11
Several checkpoints are available in the cell cycle, and
these checkpoints are crucial in preventing abnormal or
cancer cells from replicating. When a checkpoint detects
the abnormality of a cell, signals for repair and
apoptosis are initiated. Supplementation of the cell
culture medium plays a pivotal role in modulating
available checkpoints. For instance, high L-fucose
concentrations cause fucosylation, which subsequently
produces molecules that could prevent apoptosis.
Normal and cancer cells similarly require nutrients to
replicate. Treatment with high concentrations of fucose
is expected to cause either up- or downregulation of
molecules that are important to cell replication. In
addition, when treated with high concentrations of
fucose, normal and cancer cell lines could show similar
or different effects in terms of cell viability. Therefore,
the cell viability patterns of normal and cancer cell lines
treated with high concentrations of fucose should be
investigated to explore possible treatments for cancer.
Information related to these patterns could be used to
improve cancer therapy in the near future. Herein, this
study aimed to investigate the viability patterns of
human cancer and normal cell lines treated with three
different concentrations of fucose.

Methods
Selection and preparation of cancer and normal cell
lines. Three cell lines were used in this study, namely,
the human colorectal adenocarcinoma (HT-29, ATCC
HTB-38, USA) cell line, the human malignant
melanoma (A375, ATCC CRL-1619, USA) cell line,
and the human gingival fibroblast (HGF-1, ATCC CRL2014, USA) cell line. In this work, the colorectal
adenocarcinoma and malignant melanoma cell lines
were used to examine the effects of fucose treatment on
the internal and external parts of the body, respectively.
The human gingival fibroblast cell line was selected
because cells of the mouth are the first site in which
metabolism takes place.
Selection of monosaccharides. The monosaccharide
used in this study, L-fucose, was procured from Nacalai
Tesque Inc. (Kyoto, Japan) in powder form.

bovine serum (FBS) and 1% penicillin + streptomycin
solution. Four incubation periods of 1, 3, 5, and 10 days
were applied as a treatment parameter to study the effect
of fucose on the cell viability of the tested cell lines.
Cell culture technique. The HT-29, A375, and HGF-1
cells were thawed and revived in a 25 ml culture flask
containing basal medium and incubated overnight at the
optimum temperature of 37 ℃ with 5% CO2 and 90%
humidity. The medium was changed after 3 days of
incubation to ensure sufficient nutrients for the cells to
develop and grow. Cell proliferation activity was
observed daily until approximately 80% confluence was
achieved. The cell cultures were then subjectively
observed by comparing occupied and unoccupied areas.
Upon reaching confluence, the cells were dissociated
using dissociation media and then seeded.
Viability test by MTT assay. MTT assay was
conducted to assess the metabolic activity of the cells.
Prior to the cell viability test, the cells were counted
using a hemocytometer by adopting the method from
previous study.13 Approximately 1000 cells were
aliquoted into different 12-well plates containing
DMEM that had been added with 10% FBS, 1%
antibiotics, and fucose. Plates with fucose were
incubated for 1, 3, 5, and 10 days.
The treated cell lines were washed with phosphate
buffer saline. Then, 20 µl of 0.5 mg/ml MTT solution
was added to each well, and the plates were incubated
for at least 2 hours. The MTT solution was then
removed, and the wells were added with 200 µl of
dimethyl sulfoxide to solubilize the formazan crystals.
Absorbance was measured using a spectrophotometer at
450 nm. Because all cell viability procedures were
considered light-sensitive processes, the plates were
wrapped with aluminum foil.
Analysis of data. Data were analyzed by using
Statistical Package for the Social Sciences software. All
treatment groups were compared with the control group,
and values are expressed as standard error mean ±
standard deviation. Significant differences between
treatment groups and the control were determined using
one-way ANOVA. A p ≤ 0.05 was considered to
indicate statistical significance.

Results
Optimization of concentration and treatment period.
The methods used to optimize the concentration and
treatment period for in vitro stability studies were
adapted and modified from a previous study.12 Fucose
was diluted properly to three different concentration of
1, 5, and 10 mg/ml. The monosaccharide was dissolved
completely in DMEM to ensure no possible physical
effect toward the cell lines. The control for this study
was composed of DMEM containing only 10% fetal
Makara J Health Res.

Table 1 reveals the cell viability of the normal HGF-1
cell line after treatment with fucose. Comparison of the
cell viability patterns of the control and different
treatment groups reveals remarkable differences. This
result indicates that the cell viability pattern of control
group is likely similar to that of normal cell growth. All
of the treatment groups showed a drastic decline in cell
viability after day 3 of treatment, a slight increase on
August 2020 | Vol. 24 | No. 2
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day 5, and another decrease on day 10. While the effect
of 5 mg/ml fucose on cell viability on day 10 seems to
be less extensive than that of 10 mg/ml fucose, the
observed viability patterns are similar.

71

to day 10. Treatment of A375 cells with 5 and 10 mg/ml
fucose revealed no increase for the cell viability which
the cells continue to decline from day 1 until day 10.
Unlike HGF-1 cells, these cancer cells were able to
withstand the effects of high fucose concentrations;
thus, the cell viability of this line did not decline on
days 5 and 10 in comparison with that of the HGF-1
line. Fucose treatment resulted in concentrationdependent decreases in cell viability. However, cell
viability after treatment with 5 mg/ml fucose on day 10
appeared to be higher than that observed after treatment
with 1 mg/ml fucose.

Table 2 illustrates the viability of A375 cells after
treatment with fucose. The control and 1 mg/ml fucose
treatment groups showed similar patterns of cell
viability, which means 1 mg/ml fucose does not affect
cell viability. The control and 1 mg/ml fucose treatment
groups showed continuous increases in cell viability
from day 1 to day 3. Cell viability declined from day 5

Table 1. Percentage of HGF cell viability after treatment with 1, 5, and 10 mg/ml fucose (p < 0.001)
Untreated (%)

1 mg/ml (%)

5 mg/ml (%)

10 mg/ml (%)

Day 1

Day

100.00

98.21

98.92

99.48

Day 3
Day 5
Day 10

97.62
111.27
87.80

5.50
6.50
2.10

5.19
5.96
1.43

5.26
6.64
2.05

Table 2. Percentage of A375 cell viability after treatment with 1, 5, and 10 mg/ml fucose (p < 0.001)
Untreated (%)

1 mg/ml (%)

5 mg/ml (%)

10 mg/ml (%)

Day 1

Day

100.00

105.70

106.41

113.78

Day 3
Day 5
Day 10

138.22
49.02
22.31

102.20
40.03
3.97

96.54
49.54
11.25

92.36
41.07
10.06

Table 3. Percentage of HT-29 cell viability after treatment with 1, 5, and 10 mg/ml fucose (p < 0.001)
Day

Untreated (%)

1 mg/ml (%)

5 mg/ml (%)

10 mg/ml (%)

Day 1

100.00

102.06

102.76

109.63

Day 3
Day 5
Day 10

159.85
139.71
69.57

130.67
105.87
46.80

98.77
89.85
59.87

85.68
76.27
53.17

Table 4. Comparison of HGF–Fucose, A375–Fucose, and HT-29–Fucose using One-way ANOVA
Fucose

Sum of Squares

Df

Mean Square

F

p

0.065
0.009
0.074

15
80
95

0.004
< 0.001

38.982

< 0.001

46.485
42.888
89.373

15
444
459

3.099
0.097

32.083

< 0.001

44.186
4.463
48.649

15
464
479

2.946
0.010

306.272

< 0.001

HGF– Fucose
Between Groups
Within Groups
Total
A375 – Fucose
Between Groups
Within Groups
Total
HT-29 – Fucose
Between Groups
Within Groups
Total
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Table 3 shows the cell viability patterns of HT-29 cells
after treatment with fucose. The cell viability of the
control group indicated an increment from day 1 to day
3. Cell viability then declined from day 5 to 10. By
contrast, the cell viability of all treatment groups
declined from day 1 to day 10. In addition, on day 1,
cell viability increased as the treatment concentration
increased. An increase in cell viability was also
observed on days 5 and 10 after treatment with 5 mg/ml
fucose. By comparison, cell viability decreased after
treatment with 10 mg/ml fucose. Table 4 shows that the
results of ANOVA are highly significant with p < 0.001.

Discussion
Cellular growth may be categorized into four
important phases. A previous study explained the
phases of cellular growth. 14 The first phase is known
as the lag phase. During this phase, cellular adaptation
to the new environment takes place, new enzymes are
synthesized, and a slight increase in cell mass and
volume occurs, but the cell number does not increase.
The second phase is the exponential phase, during
which balanced growth, that is, all cell components
grow at a similar rate, occurs. In the phase, the cells
have adjusted to their new environment and replicate
exponentially. The growth rate is independent of the
nutrient concentration because nutrients are in excess
in this phase. The third phase, the stationary phase,
begins when the net growth rate is equal to zero.
Finally, the declining or death phase is characterized
by a decrease in the living cell population over time
because of a lack of nutrients and increase in the
amount of toxic metabolic by-products.
Excess fucose in the medium would affect the cell
growth of normal and cancer cell lines. According to
the findings in this study, excess fucose presents a
level of toxicity that causes normal human gingival
fibroblasts to die. This toxic effect could be due to the
oxidative stress effect. The oxidation process of fucose
yields toxic metabolic by-products. Yorek and Dunlap
reported that L-fucose causes the generation of
reactive oxygen species (ROS) and activation of NFkB after cellular processing. 15 Excess ROS has been
reported to cause DNA damage, which subsequently
leads to cell death. 16 NF-kB plays an important role in
causing apoptosis, which is also known programmed
cell death.17 Therefore, normal cells die under high
concentrations of L-fucose.
The cell viability patterns of the cancer cells reveal
that these cells could adapt to a new environment.
Moreover, the results indicate that cancer cells could
survive treatment with excess monosaccharides, which
may be due to the disruption of the apoptotic pathway.
For instance, a previous study reported that mutations
or downregulation of molecules involved in the Fas
Makara J Health Res.

receptor–Fas ligand (FasR–FasL) apoptotic pathway
are well-known mechanisms exploited by cancer cells
to escape apoptosis. 7 Elevation of ROS in cancer cells
is a hallmark of cancer cell progression. Recent studies
have demonstrated that cancer cells are highly adaptive
to elevated levels of ROS by activating antioxidant
pathways. ROS play a vital role in cancer
development, including initiation, promotion, and
progression.16 Increased intracellular ROS levels may
activate oncogenes and oncogenic signals, including
constitutively active mutant Ras, Bcr-Abl, and c-Myc,
all of which are involved in cell proliferation,
inactivation of tumor suppressor genes, angiogenesis,
and mitochondrial dysfunction. 16
Glycosylation is an enzyme-directed site-specific
process that links saccharides to produce glycans,
which, in turn, are attached to proteins, lipids, or other
organic molecules. 18 Glycosylation is one of the most
important posttranslational modifications and related
to many different diseases. 19 It is involved in numerous
essential biological processes, such as cell
proliferation, differentiation, migration, cell–cell
integrity and recognition, and immune modulation. 19
As mentioned earlier, fucosylated glycans have
functions in inflammatory response regulation, signal
transduction, cell growth, transcription, and adhesion.
For example, cell–cell interactions can be partially
modulated by the presence of L-fucose-specific lectinlike adhesion molecules on the cell surface. 3 Breast
cancer tissues overexpress fucosylated glycans, such
as sialyl-Lewis X/A, and α-1,3/4-fucosyltransferases to
promote disease progression and metastasis. 20
Although the biological roles of L-fucose remain
unclear, the monosaccharide is known to accelerate the
malignant potential of cancer cells. 21 Previous research
on human breast cancer suggested that α-L-fucose is
not a bystander molecule but a pathophysiological
effector.22 Indeed, α-L-fucose has been proposed to be
an important component of the malignant and
metastatic phenotypes of human breast cancer. 22 Other
studies conducted using cell lines derived from several
adenocarcinomas, certain melanomas, and some
leukemias and lymphomas reveal drastic differences in
the glycan expression of neoplastic cells in comparison
with that of normal cells. 22 In 2010, glycans were
shown to be intrinsically important in the pathobiology
of most common human malignancies. 23 A review
paper reported the role of fucosylated ligands in
human breast cancer, particularly as expressed in
CD44 variants.22 Cancer cells directly take up Lfucose and secrete fucoproteins. 21 Fucoproteins are
glycoproteins containing fucose sugar units as one of
their carbohydrates. 18 Changes in fucoprotein could
help determine the cancer diagnosis and prognosis. 24
An increase in enzymes involved in fucosylation would
result in increased levels of fucosylated proteins. 25
August 2020 | Vol. 24 | No. 2
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Physiologically, serum concentrations of L-fucose are
generally low in normal persons but high in cancer
patients.26,27 An earlier study reported that fucose
levels are higher in serum and tissue of the cancer
patients.28 Elevation of L-fucose levels in the serum
and body fluids may be attributed to the release of
glycoproteins from the tissue as a result of cell
destruction or the local synthesis and secretion of
glycoproteins by tumor cells. 21 However, some
investigators believe that an increase in serum Lfucose levels reflects tissue proliferation rather than
tissue destruction. 3,29 Fucosylated haptoglobin, which
appears in the serum of some cancer patients, may be a
promising biomarker for the prognosis of colorectal
cancer.30

Funding
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